Mintz

Federal energy and infrastructure policy remains dynamic, with policymakers focused on three interrelated challenges: strengthening domestic supply chains, expanding reliable power generation (particularly nuclear), and upgrading the electric grid to meet rising demand. Recent federal actions — including major nuclear financing, new grid oversight measures, and permitting reforms — signal an effort to accelerate project development while managing costs and regulatory complexity.

Law.com featured Sige Gutman in a Q&A about his career and how it led him to become the Chair of Mintz’s Life Sciences Litigation Practice. In the profile, Sige discusses how he discovered his fondness for life sciences patent law, his path toward leadership, and advice for others on how to effectively lead while balancing a sophisticated legal practice. Sige describes the necessary skills for being an effective practice leader: “First off, advanced legal expertise is essential.

In this issue of Telephone and Texting Compliance News, we look at new FCC regulatory proposals around KYC, KYUP, and telephone numbering reforms that signal a more demanding compliance environment across the provider ecosystem. On the litigation front, we highlight a recent Texas court decision that underscores how effective early defenses can be in TCPA litigation. In Sutton v.

Amendments to the Texas mini-TCPA significantly expanded its reach by requiring certain businesses to obtain a registration certificate from the Texas secretary of state. Against this backdrop, one recent decision is a useful reminder of the statute’s significant exemptions. In Sutton v. Senior Life Insurance Company, No. 25-cv-397, 2026 WL 1611881 (W.D. Tex.

On June 25, 2026, Senate HELP Committee Chairman Bill Cassidy (R-LA) released a sweeping legislative discussion draft titled the 340B Drug Pricing Integrity and Affordability for Patients Act. This proposal represents the most significant proposed overhaul of the 340B Drug Pricing Program in more than 15 years — and if enacted, it would have profound implications for every hospital, health system, and safety-net provider currently participating in the program.

Over the past few months, the Federal Communications Commission (FCC) has taken a number of new steps to pursue what Chairman Brendan Carr first described in October 2025 as a “different approach” to illegal robocalls: targeting the problem “at every point of the call path” by placing more responsibility on voice service providers to police their networks and the traffic they accept from others.

In our last post, we covered the trials and tribulations of companies that treat confidential information the same as trade secrets and pay the price for it. Today, we are covering the next consideration when establishing trade secret protections: how do you determine what is trade secret-worthy or not? Why It Matters Not everything confidential is a trade secret, and over-designating is a fast way to protect nothing.

Elissa Flynn-Poppey and Edmund Daley were recognized with a ‘shout-out’ for Litigator of the Week by The American Lawyer’s Litigation Daily for securing a significant victory before the Massachusetts Supreme Judicial Court. The court ruled that a proposed statewide rent control ballot initiative could not appear on the ballot because it would have impermissibly considered religion in determining whether a property was subject to rent control under the Massachusetts Constitution.

Mintz advised the underwriters in connection with MoonLake Immunotherapeutics’ $200 million public offering of Class A ordinary shares. Leerink Partners, Guggenheim Securities, Cantor and LifeSci Capital acted as joint bookrunning managers for the offering. H.C. Wainwright & Co. and Clear Street acted as lead managers for the offering. The Mintz capital markets team included William Hicks, John Rudy, Nishant Dharia, Jocelyn Sun, and Paty Garza-Gonzalez.

Mintz advised the placement agent in connection with CalciMedica’s up to $49 million private placement. The private placement included (i) shares of common stock or pre-funded warrants to purchase shares of common stock, (ii) a right to receive Series A warrants and (iii) a right to receive Series B warrants. The Series A warrants and Series B warrants are issuable subject to stockholder approval. Guggenheim Securities acted as sole placement agent.